JP2016503295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503295A5 JP2016503295A5 JP2015540250A JP2015540250A JP2016503295A5 JP 2016503295 A5 JP2016503295 A5 JP 2016503295A5 JP 2015540250 A JP2015540250 A JP 2015540250A JP 2015540250 A JP2015540250 A JP 2015540250A JP 2016503295 A5 JP2016503295 A5 JP 2016503295A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723545P | 2012-11-07 | 2012-11-07 | |
| US61/723,545 | 2012-11-07 | ||
| US201361749610P | 2013-01-07 | 2013-01-07 | |
| US61/749,610 | 2013-01-07 | ||
| US201361886156P | 2013-10-03 | 2013-10-03 | |
| US61/886,156 | 2013-10-03 | ||
| US201361889179P | 2013-10-10 | 2013-10-10 | |
| US61/889,179 | 2013-10-10 | ||
| PCT/IB2013/059786 WO2014072888A1 (en) | 2012-11-07 | 2013-10-30 | Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016503295A JP2016503295A (ja) | 2016-02-04 |
| JP2016503295A5 true JP2016503295A5 (enExample) | 2016-12-22 |
Family
ID=49955428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540250A Pending JP2016503295A (ja) | 2012-11-07 | 2013-10-30 | 抗ｉｌ−１３受容体アルファ２抗体および抗体−薬物コンジュゲート |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9828428B2 (enExample) |
| EP (1) | EP2916875A1 (enExample) |
| JP (1) | JP2016503295A (enExample) |
| KR (1) | KR101763499B1 (enExample) |
| CN (1) | CN104936621A (enExample) |
| AU (1) | AU2013343111A1 (enExample) |
| CA (1) | CA2890256A1 (enExample) |
| HK (1) | HK1214161A1 (enExample) |
| IL (1) | IL238566A0 (enExample) |
| MX (1) | MX2015005582A (enExample) |
| PE (1) | PE20150891A1 (enExample) |
| PH (1) | PH12015500977A1 (enExample) |
| RU (1) | RU2015116485A (enExample) |
| SG (1) | SG11201503431TA (enExample) |
| WO (1) | WO2014072888A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3539982B1 (en) | 2011-12-23 | 2025-02-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| CR20160319A (es) * | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| RU2747989C2 (ru) * | 2014-05-28 | 2021-05-18 | Эдженсис, Инк. | Производные пептидов долапроин-долаизолейина |
| US10647768B2 (en) | 2014-05-29 | 2020-05-12 | Macrogenics, Inc. | Multi-chain polypeptide-containing tri-specific binding molecules |
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| EP3207128B1 (en) | 2014-10-17 | 2022-07-27 | Kodiak Sciences Inc. | Butyrylcholinesterase zwitterionic polymer conjugates |
| KR102672113B1 (ko) | 2015-02-16 | 2024-06-03 | 론자 리미티드 | Cl 및/또는 ch1 돌연변이된 약물 접합용 항체 |
| HK1251480A1 (zh) | 2015-09-21 | 2019-02-01 | Aptevo Research And Development Llc | Cd3结合多肽 |
| TWI812873B (zh) * | 2015-11-30 | 2023-08-21 | 美商輝瑞股份有限公司 | 用於部位專一性接合之抗體和抗體片段 |
| US10689458B2 (en) | 2015-11-30 | 2020-06-23 | Pfizer Inc. | Site specific HER2 antibody drug conjugates |
| CN108367069B (zh) | 2015-12-14 | 2022-08-23 | 宏观基因有限公司 | 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 |
| CN107405408B (zh) * | 2015-12-21 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | 一种抗体药物偶联物的制备方法 |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| US20190086392A1 (en) | 2016-03-21 | 2019-03-21 | Inserm (Institut National De La Sante Et De La Recherch Medicale) | Methods for diagnosis and treatment of solar lentigo |
| MX2018014950A (es) | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
| CN108456250B (zh) | 2017-02-17 | 2025-11-28 | 恺兴生命科技(上海)有限公司 | 靶向il-13ra2的抗体及其应用 |
| CN107880131A (zh) * | 2017-08-14 | 2018-04-06 | 四川大学 | 一种抗IL‑13Rα2和CD3双特异抗体及其应用 |
| US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
| US11795226B2 (en) | 2017-12-12 | 2023-10-24 | Macrogenics, Inc. | Bispecific CD16-binding molecules and their use in the treatment of disease |
| CN111787949A (zh) | 2018-02-15 | 2020-10-16 | 宏观基因有限公司 | 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途 |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| WO2019178085A1 (en) | 2018-03-14 | 2019-09-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy |
| JP7438123B2 (ja) * | 2018-03-14 | 2024-02-26 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | 腫瘍特異的Ｔ細胞免疫療法用のＩＬ－１３受容体α２（ＩＬ１３Ｒα２）標的キメラ抗原受容体 |
| US12109273B2 (en) | 2019-02-15 | 2024-10-08 | Wuxi Xdc Singapore Private Limited | Process for preparing antibody-drug conjugates with improved homogeneity |
| JP7232925B2 (ja) * | 2019-02-15 | 2023-03-03 | ウーシー バイオロジクス アイルランド リミテッド | 改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| JP7745556B2 (ja) | 2020-02-21 | 2025-09-29 | マクロジェニクス，インコーポレーテッド | Ｃｄ１３７結合分子及びその使用 |
| CA3173893A1 (en) * | 2020-05-15 | 2021-11-18 | Di YU | Anti-il13r.alpha.2 antibodies, antigen-binding fragments and uses thereof |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| CN117043192B (zh) * | 2021-02-19 | 2024-05-03 | 上海齐鲁制药研究中心有限公司 | 针对IL-13Rα2的抗体及其应用 |
| CN117396498A (zh) * | 2021-03-18 | 2024-01-12 | 威斯塔解剖学和生物学研究所 | 靶向IL13Rα2的DNA编码的双特异性抗体以及在癌症治疗中的使用方法 |
| AU2022301099A1 (en) | 2021-07-01 | 2024-02-15 | Ningbo T-Maximum Biopharmaceuticals Co., Ltd. | Antigen-binding polypeptide targeting b7h3 and application thereof |
| WO2023274380A1 (zh) * | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向IL13Rα2的通用型CAR-T细胞及其制备方法和应用 |
| KR20240150782A (ko) * | 2022-02-17 | 2024-10-16 | 라노바 메디신즈 디벨롭먼트 컴퍼니 리미티드 | 항-il-13ra2 단클론성 항체 및 그것의 용도 |
| US20260151429A1 (en) * | 2022-08-25 | 2026-06-04 | Nanjing Legend Biotech Co., Ltd. | Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof |
| CN115960257B (zh) * | 2022-09-29 | 2023-10-27 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的经优化的嵌合抗原受体及其用途 |
| CN120882864A (zh) * | 2022-09-30 | 2025-10-31 | 国立大学法人 东京大学 | 靶向il13ra2的单纯疱疹病毒及抗il13ra2抗体或其抗原结合片段 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| AU2001284978A1 (en) | 2000-08-31 | 2002-03-13 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il-13 receptor alpha chain |
| WO2004087758A2 (en) | 2003-03-26 | 2004-10-14 | Neopharm, Inc. | Il 13 receptor alpha 2 antibody and methods of use |
| WO2005042028A2 (en) | 2003-10-27 | 2005-05-12 | Neopharm, Inc. | Il-13 conjugated to an immunogen and uses thereof |
| ES2501947T3 (es) | 2006-10-19 | 2014-10-02 | Csl Limited | Antagonistas de anticuerpos de alta afinidad del receptor alfa 1 de interleucina |
| PL2068922T3 (pl) | 2006-10-19 | 2012-11-30 | Csl Ltd | Przeciwciała anty-IL-13R alfa1 i ich zastosowania |
| JP2010190572A (ja) | 2007-06-01 | 2010-09-02 | Sapporo Medical Univ | ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬 |
| SG186451A1 (en) | 2010-07-12 | 2013-01-30 | Covx Technologies Ireland Ltd | Multifunctional antibody conjugates |
| EP2780039B9 (en) | 2011-11-17 | 2018-04-18 | Pfizer Inc | Cytotoxic peptides and antibody drug conjugates thereof |
| EP3539982B1 (en) | 2011-12-23 | 2025-02-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| US20130323234A1 (en) | 2012-01-09 | 2013-12-05 | Covx Technologies Ireland Limited | Mutant antibodies and conjugation thereof |
-
2013
- 2013-10-30 KR KR1020157011436A patent/KR101763499B1/ko not_active Expired - Fee Related
- 2013-10-30 MX MX2015005582A patent/MX2015005582A/es unknown
- 2013-10-30 AU AU2013343111A patent/AU2013343111A1/en not_active Abandoned
- 2013-10-30 HK HK16102252.1A patent/HK1214161A1/zh unknown
- 2013-10-30 SG SG11201503431TA patent/SG11201503431TA/en unknown
- 2013-10-30 WO PCT/IB2013/059786 patent/WO2014072888A1/en not_active Ceased
- 2013-10-30 RU RU2015116485A patent/RU2015116485A/ru not_active Application Discontinuation
- 2013-10-30 JP JP2015540250A patent/JP2016503295A/ja active Pending
- 2013-10-30 EP EP13820931.7A patent/EP2916875A1/en not_active Withdrawn
- 2013-10-30 CA CA2890256A patent/CA2890256A1/en not_active Abandoned
- 2013-10-30 US US14/439,897 patent/US9828428B2/en active Active
- 2013-10-30 PE PE2015000568A patent/PE20150891A1/es not_active Application Discontinuation
- 2013-10-30 CN CN201380057103.5A patent/CN104936621A/zh active Pending
-
2015
- 2015-04-30 IL IL238566A patent/IL238566A0/en unknown
- 2015-04-30 PH PH12015500977A patent/PH12015500977A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015116485A (ru) | Антитела к рецептору альфа 2 интерлейкина-13 и конъюгаты антитело-лекарственное средство | |
| JP2020023523A5 (enExample) | ||
| ES2773504T3 (es) | Nuevo polipéptido que tiene afinidad por PD-L1 | |
| JP2020502271A5 (enExample) | ||
| JP2022512132A (ja) | 抗クローディン抗体及びそれらの使用 | |
| CA2595610A1 (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
| ES2662418T3 (es) | Agentes de unión a TNF mejorados | |
| JP2010535713A5 (enExample) | ||
| JP2019512242A5 (enExample) | ||
| JP2017186337A5 (enExample) | ||
| RU2013142004A (ru) | Конъюгаты "антитело-лекарственное средство" | |
| JP2011505146A5 (enExample) | ||
| JP2017531028A5 (enExample) | ||
| IL278574B1 (en) | Glycan-interacting compounds and methods of use | |
| JP2020511936A5 (enExample) | ||
| JP2015516985A5 (enExample) | ||
| JP2008532523A5 (enExample) | ||
| JP2013502913A5 (enExample) | ||
| JP2009506790A5 (enExample) | ||
| JP2012100677A5 (enExample) | ||
| JP2010511388A5 (enExample) | ||
| JP2009505676A5 (enExample) | ||
| JP2016523810A5 (enExample) | ||
| JP2017537620A5 (enExample) | ||
| JP2017526339A5 (enExample) |